Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer
<i>Background: </i>Estimation of life expectancy in older patients is relevant to select the best treatment strategy. We aimed to develop and validate a score to predict early mortality in older patients with cancer. <i>Patients and Methods:</i> A total of 749 patients over 7...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/8/1615 |
id |
doaj-dec82369e24346948956c24229cd658e |
---|---|
record_format |
Article |
spelling |
doaj-dec82369e24346948956c24229cd658e2021-04-10T23:02:56ZengMDPI AGJournal of Clinical Medicine2077-03832021-04-01101615161510.3390/jcm10081615Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for CancerJaime Feliu0Alvaro Pinto1Laura Basterretxea2Borja López-San Vicente3Irene Paredero4Elisenda Llabrés5Beatriz Jiménez-Munárriz6Maite Antonio-Rebollo7Beatriz Losada8Enrique Espinosa9Regina Gironés10Ana Belén Custodio11María del Mar Muñoz12Mariana Díaz-Almirón13Jenifer Gómez-Mediavilla14María Dolores Torregrosa15Gema Soler16Patricia Cruz17Oliver Higuera18Juan Ignacio González-Montalvo19María José Molina-Garrido20Oncology Department, Hospital Universitario La Paz. IDIPAZ, Cátedra UAM-AMGEN, CIBERONC, 28046 Madrid, SpainOncology Department, Hospital Universitario La Paz. IDIPAZ, Cátedra UAM-AMGEN, CIBERONC, 28046 Madrid, SpainOncology Department, OSI Donostialde, Donostialde, 20014 Donostia, Gipuzkoa, SpainOncology Department, OSI Bilbao, 48013 Bilbao, SpainOncology Department, Hospital Universitario Dr. Peset, 46017 Valencia, SpainOncology Department, Hospital Universitario Insular de Gran Canarias, 35016 Las Palmas, SpainOncology Department, Centro Integral Oncológico Clara Campal, 28050 Madrid, SpainOncohematogeriatrics Unit, Institut Català d’Oncologia. IDIBELL, 08908 Hospitalet, Barcelona, SpainOncology Department, Hospital Universitario de Fuenlabrada, 28942 Fuenlabrada, SpainOncology Department, Hospital Universitario La Paz. IDIPAZ, Cátedra UAM-AMGEN, CIBERONC, 28046 Madrid, SpainOncology Department, Hospital Universitari y Politécnic La Fé, 46026 Valencia, SpainOncology Department, Hospital Universitario La Paz. IDIPAZ, Cátedra UAM-AMGEN, CIBERONC, 28046 Madrid, SpainOncology Department, Hospital Virgen de la Luz, 16002 Cuenca, SpainBiostatistics Department, Hospital La Paz, Universidad Autónoma de Madrid, 28046 Madrid, SpainOncology Department, OSI Donostialde, Donostialde, 20014 Donostia, Gipuzkoa, SpainOncology Department, Hospital Universitario Dr. Peset, 46017 Valencia, SpainOncohematogeriatrics Unit, Institut Català d’Oncologia. IDIBELL, 08908 Hospitalet, Barcelona, SpainOncology Department, Hospital Universitario La Paz. IDIPAZ, Cátedra UAM-AMGEN, CIBERONC, 28046 Madrid, SpainOncology Department, Hospital Universitario La Paz. IDIPAZ, Cátedra UAM-AMGEN, CIBERONC, 28046 Madrid, SpainGeriatric Department, Hospital Universitario La Paz, IDIPAZ, 28046 Madrid, SpainOncology Department, Hospital Virgen de la Luz, 16002 Cuenca, Spain<i>Background: </i>Estimation of life expectancy in older patients is relevant to select the best treatment strategy. We aimed to develop and validate a score to predict early mortality in older patients with cancer. <i>Patients and Methods:</i> A total of 749 patients over 70 years starting new chemotherapy regimens were prospectively included. A prechemotherapy assessment that included sociodemographic variables, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and early death was examined using multivariable logistic regression. Score points were assigned to each risk factor. External validation was performed on an independent cohort. <i>Results:</i> In the training cohort, the independent predictors of 6-month mortality were metastatic stage (OR 4.8, 95% CI [2.4–9.6]), ECOG-PS 2 (OR 2.3, 95% CI [1.1–5.2]), ADL≤5 (OR 1.7, 95% CI [1.1–3.5]), serum albumin levels ≤ 3.5 g/dL (OR 3.4, 95% CI [1.7–6.6]), BMI <23 kg/m<sup>2</sup> (OR 2.5, 95% CI [1.3–4.9]), and hemoglobin levels < 11 g/dL (OR 2.4, 95% CI (1.2–4.7)). With these results, we built a prognostic score. The area under the ROC curve was 0.78 (95% CI, 0.73 to 0.84), and in the validation set, it was 0.73 (95% CI: 0.67–0.79). <i>Conclusions:</i> This simple and highly accurate tool can help physicians making decisions in elderly patients with cancer who are planned to initiate chemotherapy treatment.https://www.mdpi.com/2077-0383/10/8/1615older patientearly deathprognosticrisk scoregeriatric assessmentchemotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jaime Feliu Alvaro Pinto Laura Basterretxea Borja López-San Vicente Irene Paredero Elisenda Llabrés Beatriz Jiménez-Munárriz Maite Antonio-Rebollo Beatriz Losada Enrique Espinosa Regina Gironés Ana Belén Custodio María del Mar Muñoz Mariana Díaz-Almirón Jenifer Gómez-Mediavilla María Dolores Torregrosa Gema Soler Patricia Cruz Oliver Higuera Juan Ignacio González-Montalvo María José Molina-Garrido |
spellingShingle |
Jaime Feliu Alvaro Pinto Laura Basterretxea Borja López-San Vicente Irene Paredero Elisenda Llabrés Beatriz Jiménez-Munárriz Maite Antonio-Rebollo Beatriz Losada Enrique Espinosa Regina Gironés Ana Belén Custodio María del Mar Muñoz Mariana Díaz-Almirón Jenifer Gómez-Mediavilla María Dolores Torregrosa Gema Soler Patricia Cruz Oliver Higuera Juan Ignacio González-Montalvo María José Molina-Garrido Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer Journal of Clinical Medicine older patient early death prognostic risk score geriatric assessment chemotherapy |
author_facet |
Jaime Feliu Alvaro Pinto Laura Basterretxea Borja López-San Vicente Irene Paredero Elisenda Llabrés Beatriz Jiménez-Munárriz Maite Antonio-Rebollo Beatriz Losada Enrique Espinosa Regina Gironés Ana Belén Custodio María del Mar Muñoz Mariana Díaz-Almirón Jenifer Gómez-Mediavilla María Dolores Torregrosa Gema Soler Patricia Cruz Oliver Higuera Juan Ignacio González-Montalvo María José Molina-Garrido |
author_sort |
Jaime Feliu |
title |
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer |
title_short |
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer |
title_full |
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer |
title_fullStr |
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer |
title_full_unstemmed |
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer |
title_sort |
development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-04-01 |
description |
<i>Background: </i>Estimation of life expectancy in older patients is relevant to select the best treatment strategy. We aimed to develop and validate a score to predict early mortality in older patients with cancer. <i>Patients and Methods:</i> A total of 749 patients over 70 years starting new chemotherapy regimens were prospectively included. A prechemotherapy assessment that included sociodemographic variables, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and early death was examined using multivariable logistic regression. Score points were assigned to each risk factor. External validation was performed on an independent cohort. <i>Results:</i> In the training cohort, the independent predictors of 6-month mortality were metastatic stage (OR 4.8, 95% CI [2.4–9.6]), ECOG-PS 2 (OR 2.3, 95% CI [1.1–5.2]), ADL≤5 (OR 1.7, 95% CI [1.1–3.5]), serum albumin levels ≤ 3.5 g/dL (OR 3.4, 95% CI [1.7–6.6]), BMI <23 kg/m<sup>2</sup> (OR 2.5, 95% CI [1.3–4.9]), and hemoglobin levels < 11 g/dL (OR 2.4, 95% CI (1.2–4.7)). With these results, we built a prognostic score. The area under the ROC curve was 0.78 (95% CI, 0.73 to 0.84), and in the validation set, it was 0.73 (95% CI: 0.67–0.79). <i>Conclusions:</i> This simple and highly accurate tool can help physicians making decisions in elderly patients with cancer who are planned to initiate chemotherapy treatment. |
topic |
older patient early death prognostic risk score geriatric assessment chemotherapy |
url |
https://www.mdpi.com/2077-0383/10/8/1615 |
work_keys_str_mv |
AT jaimefeliu developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT alvaropinto developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT laurabasterretxea developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT borjalopezsanvicente developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT ireneparedero developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT elisendallabres developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT beatrizjimenezmunarriz developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT maiteantoniorebollo developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT beatrizlosada developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT enriqueespinosa developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT reginagirones developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT anabelencustodio developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT mariadelmarmunoz developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT marianadiazalmiron developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT jenifergomezmediavilla developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT mariadolorestorregrosa developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT gemasoler developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT patriciacruz developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT oliverhiguera developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT juanignaciogonzalezmontalvo developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer AT mariajosemolinagarrido developmentandvalidationofanearlymortalityriskscoreforolderpatientstreatedwithchemotherapyforcancer |
_version_ |
1721531652655546368 |